Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Imnovid pomalidomide regulatory update

The European Commission approved Imnovid pomalidomide from Celgene to treat patients with relapsed and refractory multiple myeloma (MM). Imnovid is approved in combination

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE